#USA #New York #Securities Class Action #Faruqi & Faruqi #Gossamer Bio

Gossamer Bio Investors Alert: Class Action Deadline Approaching

Faruqi & Faruqi, LLP, a prominent national securities law firm, has issued a vital reminder for investors in Gossamer Bio, Inc. (NASDAQ: GOSS) about an impending opportunity to participate in a federal securities class action. The deadline to file for lead plaintiff status in this case is set for June 1, 2026. This is a critical moment for individuals who acquired Gossamer's securities between June 16, 2025, and February 20, 2026, as they may be entitled to compensation due to alleged violations of federal securities laws.

Background of the Case

The firm is currently investigating claims suggesting that Gossamer Bio, along with its executives, made misleading statements regarding the Phase 3 PROSERA study. This study became the focus of scrutiny after its results were released on February 23, 2026, revealing that it failed to meet the primary endpoint, specifically improving patients' six-minute walk distance after 24 weeks.

According to the company, while there was a placebo-adjusted gain of +13.3 meters, this result failed to meet the required statistical significance threshold of 0.025, as it was reported at a p-value of 0.0320. The disappointing results were partially attributed to an unexpectedly strong placebo response among participants at Latin American sites, characterized as lower-risk individuals who had received extensive treatment.

As soon as these results were disclosed, the financial consequences were swift and severe. The market responded by slashing Gossamer's share price by over 80%, from $2.13 per share on February 20 to just $0.42 by the end of the trading day on February 23. Such a drastic decline signifies the frustrations and potential losses faced by investors.

Role of Lead Plaintiff

In a class action lawsuit, the lead plaintiff is a crucial figure. This individual represents the collective interest of all affected investors and has the greatest financial stake in the case’s outcome. Investors wishing to assume this role can do so through their legal representation, or they may opt out entirely, preserving their rights as class members without active participation. Importantly, not choosing to be a lead plaintiff will not affect one’s ability to recover damages if the class action prevails.

Faruqi & Faruqi encourages any party with pertinent information about Gossamer Bio's actions, including former employees, shareholders, and whistleblowers, to reach out. Information can be submitted contact directly with the firm via the provided numbers or through their official website.

Conclusion

The upcoming deadline of June 1, 2026, presents a significant opportunity for those who have incurred losses in Gossamer Bio stock. As the investigation continues, affected investors are urged to keep abreast of developments and consider their options carefully. Faruqi & Faruqi is committed to ensuring that shareholders are informed and can make educated decisions regarding their investments. For further updates and assistance, stakeholders are encouraged to follow the firm on their social media platforms or reach out directly for consultations.

For more information, visit www.faruqilaw.com/GOSS or contact Faruqi & Faruqi partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310).